Every 8-K that Option Care Health, Inc. (OPCH) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow OPCH and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPCH filings page.
Option Care Health, Inc. reported second quarter 2026 net revenue of $1,442 million, up 1.9% year over year. GAAP net income was $53.9 million and diluted EPS $0.35, increases of 6.7% and 12.9%. Adjusted EBITDA rose 3.0% to $117.5 million and adjusted diluted EPS grew 9.8% to $0.45.
Operating cash generation increased, with $184 million provided by operating activities in Q2 and $171.5 million in the first half of 2026, compared with $83.1 million a year earlier. The company repurchased $150 million of shares in the quarter. As of June 30, 2026, total assets were $3.38 billion, long-term debt was $1.15 billion and stockholders’ equity was $1.26 billion.
For full-year 2026, Option Care Health expects net revenue of $5.675–$5.775 billion, adjusted EBITDA of $480–$495 million, adjusted diluted EPS of $1.85–$1.92 and at least $320 million of operating cash flow. For third quarter 2026, it anticipates sequential low- to mid-single-digit growth in net revenue and mid-single-digit growth in adjusted EBITDA.
Option Care Health, Inc. reported results from its 2026 Annual Meeting of Stockholders held on May 20, 2026. Stockholders elected nine director nominees, each receiving over 143 million votes in favor, with additional broker non-votes recorded on each item.
Stockholders also ratified KPMG LLP as independent registered public accounting firm for the year ending December 31, 2026, with 149,076,945 votes for and 1,132,306 against. In a separate non-binding advisory vote, stockholders approved the company’s executive officer compensation, with 141,106,639 votes for and 4,192,721 against.
Option Care Health, Inc. furnished an investor presentation in connection with its participation in the Bank of America Health Care Conference. The presentation describes the company as a leading independent provider of home and alternate site infusion services.
Option Care Health reports serving over 315,000 patients in 2025 through more than 5,000 multidisciplinary clinicians, 190+ U.S. locations, about 90 full-service pharmacies, 750+ infusion chairs, and in-network status with the top 10 payers covering 96% of insured lives. For 2026, management highlights priorities that include taking actions to reaccelerate its revenue growth trajectory, reprioritizing capital allocation toward internal investments for profitable growth and share repurchases, and rebuilding momentum through coverage, conversion, and enhanced service levels.
Option Care Health, Inc. announced that Christopher L. Grashoff will depart from his role as Chief Growth Officer, effective May 8, 2026. The company states that Mr. Grashoff will receive separation benefits under its Amended and Restated Executive Severance Plan, subject to a general release of claims in favor of the company and his continued compliance with existing restrictive covenants.
Option Care Health reported mixed first quarter 2026 results, with net revenue of $1,350.7 million, up 1.3% year over year. GAAP net income was $45.3 million, down 3.0%, while GAAP diluted EPS rose to $0.29 and Adjusted diluted EPS held flat at $0.40.
Adjusted EBITDA was $104.8 million, down 6.3%, and operating activities used $12.1 million of cash. The company repurchased $17.5 million of stock and expanded its revolving credit facility from $400 million to $850 million, adding financial flexibility.
For full year 2026, Option Care Health now guides to net revenue of $5.675–$5.775 billion, Adjusted EBITDA of $480–$505 million, Adjusted diluted EPS of $1.82–$1.92, and at least $320 million of cash provided by operating activities, reflecting modest growth expectations.
Option Care Health, Inc. entered into a Fifth Amendment to its Amended and Restated First Lien Credit Agreement with Bank of America, N.A. as administrative agent. The amendment adds new revolving credit commitments totaling $450,000,000, structured as an increase to the existing Revolving Credit Commitments.
Following this change, the aggregate principal amount of Revolving Credit Commitments available under the credit agreement is $850,000,000. This amendment updates the company’s senior secured lending facility and represents additional committed borrowing capacity rather than an immediate borrowing.
Option Care Health reported solid fourth quarter and full-year 2025 results with continued growth and significant shareholder returns. Fourth quarter net revenue reached $1,465.4 million, up 8.8%, while net income was $58.5 million, down 2.7%. GAAP diluted EPS rose 5.7% to $0.37, and Adjusted EBITDA increased 3.7% to $126.0 million. The company repurchased $95 million of stock in the quarter.
For full year 2025, net revenue grew 13.0% to $5,649.5 million, with net income of $207.6 million, down 2.0%. GAAP diluted EPS increased 3.3% to $1.27, and Adjusted EBITDA rose 6.2% to $471.3 million. Adjusted diluted EPS was $1.72, up 8.9%, and operating cash flow was $258.4 million. The company repurchased $307 million of stock during the year.
Looking to 2026, Option Care Health expects net revenue of $5.8 billion to $6.0 billion, Adjusted EBITDA of $480 million to $505 million, Adjusted diluted EPS of $1.82 to $1.92, and operating cash flow of at least $340 million, signaling confidence in continued growth.
Option Care Health, Inc. disclosed that its board of directors has increased the authorization for its 2025 share repurchase program from $500 million to $1 billion, with no specified expiration date. The company may buy back stock through open market purchases, privately negotiated transactions, block trades, or accelerated and other structured repurchase programs, with volume and timing determined by management based on market, regulatory, and corporate factors.
The company also furnished a press release with preliminary financial results for the three and twelve months ended December 31, 2025 and preliminary expectations for full year 2026, and an investor presentation tied to its appearance at the 44th Annual J.P. Morgan Healthcare Conference.
Option Care Health (OPCH) furnished an update on its business by announcing it issued a press release with third quarter 2025 financial results. The press release is attached as Exhibit 99.1 to this Form 8-K. The company states the materials are furnished, not filed, which limits Exchange Act liability and incorporation by reference unless specifically noted.
The press release includes non-GAAP financial measures with reconciliations to the most comparable GAAP metrics. OPCH’s common stock trades on the Nasdaq Global Select Market under the symbol OPCH.
Option Care Health entered into a Fourth Amendment to its First Lien Credit Agreement that refinances its existing term loans into a new seven-year tranche priced at Term SOFR plus 1.75%. The amendment also provides for incremental term loans totaling $49,639,386.20 at the same rate and maturity, and extends the maturity of the revolving credit commitments to the fifth anniversary of the amendment, subject to a springing maturity 91 days prior to the Unsecured Notes maturity if any Unsecured Notes remain outstanding. After the amendment, the principal amount of First Lien Term Loan indebtedness is approximately $678,000,000. The amendment was executed by the company and Bank of America, N.A., as administrative agent.
Option Care Health, Inc. filed a Current Report on Form 8-K that attaches an Employment Offer Letter dated August 19, 2025 between the company and Meenal A. Sethna, and a Transition Agreement and Release dated August 19, 2025 between Option Care Enterprises, Inc. and Michael Shapiro. The filing also includes a Press Release dated August 20, 2025 as an exhibit and the cover page formatted in Inline XBRL. The report is signed on behalf of the company by Michael Shapiro, Chief Financial Officer on August 20, 2025.